Biotech Essentials

Companies & Industries

Biotech Companies & Industries Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 06.10.2021.

#covid19
#covidnews
#omics
#bioinformatics
#science
#CIO
#researchlife
#healthdisparities
#GoodDayBIO
#pharma

Companies And Industries

@GENbio shared
On Oct 4, 2021
RT @SnthesisInc: Incredible article here about Data Integration and Harmonization! Nice work @GENbio. Oh yeah, the article just happens to be about Snthesis! #bioinformatics #science #omics #researchlife #CIO https://t.co/l8Idp3okce
Open
Biopharma Can Dispel the Fog of Data

Biopharma Can Dispel the Fog of Data

Snthesis describes how data can be aggregated, connected, and harmonized to optimize workflows and reveal scientific insights.

@IAmBiotech shared
On Oct 5, 2021
#GoodDayBIO: What biotech needs to know about USTR’s China strategy. Also, a recent report looks at #COVID19’s impact on older Hispanic adults and provides policy recs for addressing #healthdisparities. https://t.co/7kMR8fEBH1
Open
Good Day BIO: USTR's China Strategy

Good Day BIO: USTR's China Strategy

The U.S. Trade Representative made a major policy speech yesterday on the administration’s approach to China—we tell you what biotech needs to know. Also, a recent report looks at ...

@matthewherper shared
On Oct 5, 2021
Vedanta touts positive new data for its C. diff microbiome therapeutic https://t.co/VIJJrlnPa1
Open
Vedanta touts positive new data for its C. diff microbiome therapeutic — but is it too late?

Vedanta touts positive new data for its C. diff microbiome therapeutic — but is it too late?

Vedanta revealed positive new data for its C. difficile microbiome therapeutic. But is it too late an entrant into the field?

@GENbio shared
On Oct 5, 2021
RT @isbsci: Hot off the presses: A commentary by @isbsci Co-founder Dr. Lee Hood in @GENbio. @ISBLeeHood writes about his winding, remarkable career that has spanned decades. Spoiler: He's not done yet. https://t.co/ntd43GPGAw @providence
Open
Adventures Leading to a Paradigm Shift in Healthcare

Adventures Leading to a Paradigm Shift in Healthcare

Advances in sequencing, big data technology, systems biology, and blood analysis open new paths to wellness.

@biospace shared
On Oct 4, 2021
COVID-19 update: @JNJNews to request booster authorization, @Merck antiviral review a priority #covid19 #covidnews https://t.co/pshA5trh0S
Open
COVID-19 Update: J&J to Request Booster Authorization, Merck Antiviral Review a Priority

COVID-19 Update: J&J to Request Booster Authorization, Merck Antiviral Review a Priority

Johnson & Johnson is expected to ask the U.S. Food and Drug Administration to authorize a booster for its one-shot COVID-19 vaccine this week.

@pharmaphorum shared
On Oct 1, 2021
Rumours of big #pharma interest in @AcceleronPharma prove well-founded, as @Merck breaks cover with an $11.5bn takeover deal https://t.co/3pFr8hKzdb
Open
Merck confirms $11.5bn Acceleron takeover deal

Merck confirms $11.5bn Acceleron takeover deal

Rumours of big pharma interest in Acceleron Pharma proved well-founded, as Merck breaks cover with an $11.5bn takeover deal

@GENbio shared
On Oct 5, 2021
RT @AurionBiotech: It takes a village to create high-quality cells. We've got the best people to make it happen! Thanks to @GENbio for recognizing our own VP Mfg Tim Largen and collabs with Cognate / Charles River Labs and S-RACMO https://t.co/vEWwkwnUAL
Open
Aurion Biotech Industrializing Ophthalmologic Cell-Based Therapy

Aurion Biotech Industrializing Ophthalmologic Cell-Based Therapy

The company is focusing on improving shelf life and “turn-keying” treatment protocols.

@BioWorld shared
On Oct 4, 2021
Xencor expands Janssen partnership with $1.31B licensing and development deal https://t.co/1oEeCRNckg
Open
Xencor expands Janssen partnership with $1.31B licensing and development deal

Xencor expands Janssen partnership with $1.31B licensing and development deal

Xencor Inc. and Janssen Biotech Inc., already partners on the development of bispecific antibodies against CD28 for prostate cancer, have reached a second agreement licensing to Janssen ...